Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
12.076 / 17.026
#96602

Re: Farmas USA

BLUE

Y así es como está el sector de boyante y resplandeciente, no presenta ninguna novedad para ASH y se viene un 9% abajo...

#96606

Re: Farmas USA

Entiendo que es por esto (la parte del update on clinical trials, no tanto por los números financieros, no? tampoco la sigo mucho...)

To date in the MAD study, ACH-4471 has been generally well tolerated across three dose cohorts (200 mg, 500 mg or 800 mg given every 12 hours) with no treatment-related SAEs reported. Two cases of self-limited, ALT elevations (Grade 3 and 4) were observed post-treatment in the mid- and high dose groups, respectively, with neither subject exhibiting signs or symptoms of hepatic decompensation. Both subjects' ALT levels normalized without intervention during follow up. Further, no treatment-associated fever or infections were observed.

ACHN

#96608

Re: Farmas USA

TRIL

No la sigo para nada, pero me ha hecho gracia lo siguiente

Ayer Cowen dice: Good Sign For ASH Data As '621 Advances Into Expansion Cohorts-believe '621 has potential to be a best-in-class CD47- therapy.

Hoy, liberados abstracts de ASH: -45%

Bravo!